The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

Sanofi (NASDAQ:SNY) has received FDA approval for Merilog, a biosimilar of Novo Nordisk's (NVO) rapid-acting insulin product NovoLog, for the improvement of glycemic control in adults and children ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated ...

Saudi-based Sudair Pharma Company is set to establish its new insulin plant in the Sudair City for Industry and Businesses.

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

The pen needles market valued at US$ 1.69 Billion in 2023, is forecasted to grow at a robust CAGR of 9.2%, reaching US$ 1.81 Billion in 2024 ...

The pen needles market valued at US$ 1.69 Billion in 2023, is forecasted to grow at a robust CAGR of 9.2%, reaching US$ 1.81 ...

If you were asked what did Samsung Electronics, Saudi Aramco and Kweichow Moutai have in common, besides being 3 of the ...

Internationally, it is sold in three forms by the Danish pharmaceutical company Novo Nordisk ... while Saxenda pens also deliver higher doses of 2.4mg and 3mg. Xultophy is a combination of insulin and ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t ...